Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
NCT03360630
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Neoplasms
Interventions
BIOLOGICAL:
Anti-PD-1 plus DC-CIK
BIOLOGICAL:
Anti-PD-1 alone
Sponsor
Capital Medical University
Collaborators
[object Object]
[object Object]